翰宇药业公告，预计2025年度净利润为4000万元–5000万元，同比扭亏为盈。报告期内，公司预计归属 于上市公司股东的净利润实现扭亏为盈。主要原因在于公司GLP-1制剂与原料药业务规模大幅放量， CRDMO业务落地推进。同时持续加大以创新药HY3003为首的研发投入力度，提高核心产品的竞争 力。 ...

证券代码：300199 证券简称：翰宇药业 深圳翰宇药业股份有限公司 投资者关系活动记录表 编号：2026-001 | ☐ | 特定对象调研 ☐ 分析师会议 | | --- | --- | | ☐ | 媒体采访 ☐ 业绩说明会 | | 投资者关系活动类别 | 新闻发布会 路演活动 | | ☐ | | | | 现场参观 | | | 其他 投资者开放日 | | | 招商证券、天风证券、开源证券、信达证券、兴业证券、银河证券、 | | 参与单位名称及人员姓名 | 万联证券、国海证券等多家机构及多名个人投资者。 | | 时间 | 2026年01月23日 13:30-16:00 | | | 广东省深圳市龙华区观盛四路7号翰宇创新产业园B栋一楼多功能 | | 地点 厅 | | | | 董事、执行总裁 唐洋明 | | | 董事、执行总裁 沈亚平 | | 上市公司接待人员姓名 | 副总裁、财务总监 涂鸿鸿 | | | 董事会秘书 李娉娉 | | | 一、调研参观 参观公司实验室、产品展厅。 | | | 二、公司基本情况介绍 | | | 深圳翰宇药业股份有限公司是专业从事多肽药物研、产、销一 | | 投资者关系活动主要内 ...

比《小时代》还"疯"的场景，正在硅谷上演。 原著里，顾里发现宫洺每天清晨，都会喝下一杯蓝色的生命之水，以维持高强度工作下，他精致苍白的面容和清瘦挺拔的身材。生命之水这个词，还是太 常见了；喝这个动作，还是太保守了。走在时代前沿的郭敬明估计想不到，当下硅谷精英人群的养生，已经到了Next Level——采购中国肽类原材料自行 调配、注射，用以提神、减肥、健体、抗衰，全程绕过监管。 作为热门的抗衰老疗法，近年来，生物肽成为美容、健体、养生的新秀，尤其风靡于运动员和极客中。据说上海也出现了类似的效仿现象。作为肽类产品 的全球最大供应源头，中国工厂在这场美国新潮中赚得盆满钵满。但就国内大市场而言，肽产品目前主要试水于洗护等外用品上。更保守，但也更安全。 硅谷精英，掀起注肽潮 想象一下，一名西装革履的美国精英，下班后通过秘密渠道，直接从中国的工厂购买廉价肽制剂，然后回家将这些肽制剂粉末，与无菌水混合，用注射器 注入体内。 这酷似《绝命毒师》的场景，在美国游走于法律边缘。尽管多数医生并不支持，但个人调配使用肽制剂的行为并不违规。 法律没有限制极客们拿自己的身体做实验，更没有禁止他们开Party。因此，更为疯狂的举动出现了 ...

Core Viewpoint - The article highlights the significant commercial potential of GLP-1 drugs, particularly in the context of a recent sales order by Hanyu Pharmaceutical, which marks a turning point for the company after years of losses [6][9]. Group 1: Company Developments - Hanyu Pharmaceutical has signed a sales order for GLP-1 raw materials worth approximately 180 million RMB, representing about 30% of the company's projected revenue for 2024 [6]. - The order is notable as it is a concrete commercial agreement with clear delivery and payment schedules, contrasting with typical framework collaborations or forward agreements [6]. - The company has transitioned from a domestic focus to becoming a global supply chain node, with over 70% of its revenue now coming from overseas markets, reflecting a significant shift in its business model [9]. Group 2: Market Dynamics - The global GLP-1 market is dominated by major products such as semaglutide and liraglutide, which rely heavily on stable and high-purity GLP-1 raw material supplies [7]. - There is an anticipated surge in demand for GLP-1 raw materials in China, with over ten biosimilar products expected to be approved in the next one to two years [7]. - Hanyu Pharmaceutical's production capacity for GLP-1 raw materials is approximately 5 to 8 tons annually, which accounts for over 30% of the domestic market, with plans to expand to around 10 tons [8]. Group 3: Competitive Advantages - Hanyu Pharmaceutical has achieved a production cost of approximately $3,000 per gram for GLP-1 raw materials, which is about 40% lower than similar companies in Europe and the U.S. [8]. - The company maintains a purity level of 99.9%, significantly exceeding pharmacopoeial standards, which positions it favorably in the global market for raw materials [8]. - The order from Hanyu Pharmaceutical is estimated to support the production of tens of millions of injection formulations, indicating a strong demand pull for raw materials [9].

Group 1 - The company, Hanyu Pharmaceutical, announced the approval of two key resolutions at its first extraordinary shareholders' meeting of 2026, including a proposal to apply for a credit limit from banks and provide guarantees [2] - The company also approved a resolution to change its auditing firm for the fiscal year 2025 [2]

证券代码：300199 证券简称：翰宇药业 公告编号：2026-003 深圳翰宇药业股份有限公司 及担保额度的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别风险提示： 关于2025年度向金融机构申请综合授信 为支持公司业务快速发展与战略布局，进一步拓展多元化融资渠道、优化融 资结构，公司拟向珠海华润银行股份有限公司深圳分行申请综合授信5,000.00万 元，授信产品包括流动资金贷款、商业承兑汇票、国内信用证、银行承兑汇票和 保理业务等多种产品。由全资子公司翰宇药业（武汉）有限公司（以下简称"翰 宇武汉"）及公司控股股东、实际控制人曾少贵、曾少强、曾少彬提供保证担保。 截至本公告披露日，公司及控股子公司累计对外提供担保总额占最近一期经 审计净资产134.92%、对资产负债率超过70%的单位担保金额占公司最近一期经 审计净资产66.51%；公司及子公司无对合并报表范围外的对外担保事项，也不存 在逾期担保。敬请广大投资者注意风险。 一、授信及担保审议程序 深圳翰宇药业股份有限公司（以下简称"公司"或"翰宇药业"）于2025 年2月28日召开第六届董事 ...

深圳翰宇药业股份有限公司 法律意见书 国浩律师（深圳）事务所 关于 二〇二六年第一次临时股东会 的 法律意见书 北京·上海·深圳·杭州·广州·昆明·天津·成都·宁波·福州·西安·南京·南宁·济南·重庆 Beijing·Shanghai·Shenzhen·Hangzhou·Guangzhou·Kunming·Tianjin·Chengdu ·Ningbo ·Fuzhou·Xi`an·Nanjing·Nanning·Jinan·Chongqing 苏州·长沙 ·太原·武汉·贵阳·乌鲁木齐·郑州·石家庄·合肥·海南·青岛·南昌·大连·银川·拉孜 Suzhou·Changsha·Taiyuan·Wuhan ·Guiyang·Wulumuqi·Zhengzhou·Shijiazhuang·Hefei·Hainan·Qingdao·Nanchang·Dalian·Yinchuan·Lhatse 香港·巴黎·马德里·硅谷·斯德哥尔摩·纽约·马来西亚·柬埔寨·乌兹别克斯坦·哈萨克斯坦 Hongkong·Paris·Madrid·Silicon Valley·Stockholm·New York·Malaysia·Cambod ...

证券代码：300199 证券简称：翰宇药业 公告编号：2026-002 深圳翰宇药业股份有限公司 2026年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会没有否决或变更议案的情况发生。 2、本次股东会不涉及变更前次股东会决议。 一、会议召开和出席情况 1、2025年12月30日，深圳翰宇药业股份有限公司（以下简称"公司"或"翰 宇药业"）第六届董事会第十一次会议审议通过《关于提请召开2026年第一次 临时股东会的议案》，详见公司2025年12月31日在中国证监会指定信息披露 网站（http://www.cninfo.com.cn）披露的相关公告。 2026年第一次临时股东会召开的基本情况如下： 会议召集人：公司董事会 会议方式：本次会议采取现场投票和网络投票相结合的方式 会议召开时间：2026年1月16日（周五）下午15:30 会议地点：深圳市龙华区观澜高新园区观盛四路7号翰宇创新产业大楼会 议室 会议主持人：董事长曾少贵先生 2、通过现场和网络投票的股东766人，代表股份194,510,577股，占公司 ...

Market Overview - On January 15, A-shares showed mixed performance with the Shanghai Composite Index closing at 4112.6 points, down 0.33%, while the Shenzhen Component Index rose by 0.41% and the ChiNext Index increased by 0.56% [1] - The total market turnover was approximately 2.93 trillion yuan, a decrease of over 1 trillion yuan compared to the previous trading day, with more than 2200 stocks closing higher, including 63 stocks hitting the daily limit [1] Sector Performance - The precious metals sector led the gains, with Sichuan Gold hitting the daily limit. Other sectors that saw gains included electronic chemicals, photoresists, SMIC concepts, and agricultural chemicals [1] - Conversely, sectors such as Xiaohongshu concepts, internet e-commerce, and Sora video saw significant declines [1] Historical Highs - A total of 88 stocks reached historical closing highs, with notable concentrations in the electronics, non-ferrous metals, and machinery equipment sectors, which had 25, 15, and 14 stocks respectively [2] - The average price increase for stocks reaching historical highs was 4.74%, with stocks like Dongfang Tieta and Decai Co., Ltd. hitting the daily limit, and Shanghai Xinyang, Helin Weina, and Sudawige showing significant gains [2] Institutional Activity - In the龙虎榜, 16 stocks were net bought, with 13 stocks seeing net purchases exceeding 10 million yuan. The top net buyer was Shenguang Group with 494 million yuan, followed by Sanwei Communication with 279 million yuan [5] - Conversely, the top net seller was Liou Co., Ltd. with a net sell of 432 million yuan, followed by Zhongke Xingtou, Shanzi Gaoke, and Vision China, each exceeding 200 million yuan in net sales [5] Northbound Capital Flow - Among the stocks on the龙虎榜, 10 stocks received net purchases from northbound funds, with Wolong Nuclear Materials leading at 254 million yuan. Other notable net buyers included Zhongke Xingtou, Hezhuan Intelligent, and Xidian Co., Ltd. [7] - Northbound funds sold off 23 stocks, with Shanzi Gaoke leading the net sell at 315 million yuan, which hit the daily limit down [7] Company Announcements - Gree Electric Appliances announced a mid-year dividend distribution of 10 yuan per 10 shares, with the record date set for January 22, 2025 [10] - Longpan Technology expects to have procurement transactions with Ningde Times not exceeding 7 billion yuan in 2026 [11] - Zhi Te New Materials clarified that its business does not involve AI applications and will resume trading tomorrow [12] - Zhejiang Construction reported a cumulative new contract amount of 146.816 billion yuan for the year 2025 [14] - Zhenghai Magnetic Materials expects a net profit increase of 235.72% to 311.52% year-on-year for 2025 [16] - Shengnuo Bio anticipates a net profit increase of 204% to 281% year-on-year for 2025 due to growing demand for peptide raw materials [18]

Core Viewpoint - The company, Hanyu Pharmaceutical (300199.SZ), has signed a sales order with a client for the procurement of GLP-1 active pharmaceutical ingredients amounting to 180 million RMB [1] Group 1 - The total procurement amount for the GLP-1 active pharmaceutical ingredients is 180 million RMB [1]